| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Coronary Stents Market Size 2024 |
USD 8,625 Million |
| Coronary Stents Market, CAGR |
9.14% |
| Coronary Stents Market Size 2032 |
USD 17,363.23 Million |
Market Overview
The global market for coronary stents is projected to grow significantly, increasing from USD 8,625 million in 2024 to USD 17,363.23 million by 2032, reflecting a compound annual growth rate (CAGR) of 9.14%.
The growth of the coronary stents market is primarily driven by the rising prevalence of cardiovascular diseases, increasing aging populations, and advancements in stent technology, including drug-eluting stents that reduce restenosis rates. Additionally, the growing adoption of minimally invasive procedures enhances patient outcomes and recovery times. Key trends include the integration of bioresorbable stents, which offer temporary support and reduce long-term complications, and the increasing use of remote patient monitoring technologies. Furthermore, expanding healthcare access and rising health awareness contribute to a heightened demand for innovative cardiovascular solutions, fostering market growth.
The geographical analysis of the coronary stents market reveals significant growth in North America and Europe, attributed to advanced healthcare infrastructure and high prevalence of cardiovascular diseases. North America holds the largest market share due to the presence of leading players such as Abbott, Medtronic, and Boston Scientific Corporation, which drive innovation and product availability. Meanwhile, the Asia-Pacific region is emerging as a lucrative market, fueled by rising healthcare expenditure and increasing awareness about heart diseases. Key players like Biotronik SE & Co. KG and Terumo Corporation are expanding their footprint in these markets, enhancing access to advanced stent technologies.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers
Increasing Prevalence of Cardiovascular Diseases
The global rise in cardiovascular diseases, particularly coronary artery disease (CAD), is significantly influenced by an aging population. For instance, the incidence of cardiovascular disease increases dramatically with age, affecting approximately 75% of individuals aged 60-79 years and 86% of those over 80 years. As people live longer, the incidence of heart-related ailments escalates, necessitating interventions such as coronary stents. Sedentary lifestyles and poor dietary habits further exacerbate this trend, leading to increased rates of obesity—another critical risk factor for heart disease. Moreover, the prevalence of diabetes has surged, significantly heightening the risk of cardiovascular complications and underscoring the need for effective treatments, including stent placements.
Increasing Healthcare Expenditure
Growing awareness about heart disease and its risk factors is leading to earlier diagnosis and treatment options, including stent procedures. Additionally, government initiatives aimed at enhancing healthcare access and affordability are contributing to market expansion. For instance, the use of coronary stents in China increased dramatically from 230,000 to over 1.5 million between 2009 and 2018, reflecting significant investment in healthcare infrastructure. The expansion of healthcare infrastructure in emerging markets, driven by a rising middle class and increased investments, is further facilitating access to advanced medical treatments, including coronary stents, thereby fostering market growth.
Technological Advancements
Innovations in stent technology play a pivotal role in shaping the coronary stents market. Drug-eluting stents (DES) have transformed patient outcomes by releasing medication that prevents restenosis, or the renarrowing of arteries, after placement. Additionally, bioresorbable stents (BRS) represent a groundbreaking advancement, as they dissolve over time, reducing the need for permanent implants. The development of advanced coating technologies has also enhanced stent performance, minimizing adverse events and improving patient safety.
Rising Demand for Minimally Invasive Procedures
The shift towards minimally invasive procedures is driving demand for coronary stents. Percutaneous coronary intervention (PCI) has emerged as a preferred alternative to open-heart surgery, enabling healthcare providers to place stents with less trauma to the patient. This technique not only shortens recovery times but also improves overall patient satisfaction, further fueling the growth of the coronary stents market.
Market Trends
Technological Advancements Driving Market Growth
The coronary stents market is experiencing significant growth due to continuous technological advancements. Drug-eluting stents (DES) dominate the market, primarily because of their proven effectiveness in preventing restenosis. For instance, a study published in the New England Journal of Medicine found that newer-generation DES reduced the risk of stent thrombosis by 50% compared to first-generation DES. The introduction of newer-generation DES featuring enhanced drug delivery systems and biodegradable polymers is further propelling this segment. These advancements not only improve patient outcomes but also address the limitations of earlier stent technologies. Meanwhile, bioresorbable stents (BRS) are evolving as a promising alternative, with ongoing developments aimed at enhancing performance and minimizing complications. Although BRS are still in their developmental phase, they hold substantial future potential, representing a shift towards less invasive solutions in cardiovascular treatments. Additionally, innovative coating technologies are being implemented to improve stent performance, thereby reducing adverse events and increasing the overall safety of these devices. The combination of these technological advancements ensures that coronary stents remain at the forefront of cardiac care, contributing to better treatment options for patients worldwide.
Increasing Demand for Minimally Invasive Procedures
The demand for minimally invasive procedures, particularly percutaneous coronary intervention (PCI), is a significant factor driving the coronary stents market. PCI has emerged as the preferred treatment for coronary artery disease (CAD), providing a less traumatic alternative to traditional open-heart surgery. This shift towards minimally invasive techniques not only reduces recovery time but also enhances patient satisfaction and outcomes. Furthermore, the introduction of stents specifically designed to address complex lesions, such as bifurcations and chronic total occlusions, is gaining traction among healthcare providers. These advancements are critical as they meet the growing need for effective treatments in patients with challenging cardiovascular conditions. Coupled with the aging population and the increasing prevalence of cardiovascular diseases, the rising demand for these innovative, minimally invasive procedures highlights a significant market trend. Additionally, the expansion of healthcare infrastructure in emerging markets is creating new opportunities for the adoption of coronary stents. Increased investments in healthcare and rising awareness regarding cardiovascular health in these regions are facilitating access to advanced stenting technologies. As healthcare systems evolve, the focus on cost-effectiveness and positive long-term patient outcomes further influences the development and acceptance of new stent technologies, shaping the future landscape of the coronary stents market.
Market Challenges Analysis
Product Failures and Regulatory Challenges
The coronary stents market faces significant challenges stemming from product failures and stringent regulatory requirements. Stent deformation and plaque prolapse can lead to serious complications for patients, prompting product recalls that can severely damage the reputation of manufacturers and undermine market confidence. For instance, the recall of certain stent models due to deformation issues has highlighted the critical need for rigorous quality control. Such adverse events not only disrupt production but also raise concerns about the safety and efficacy of stenting technologies. Furthermore, the regulatory environment for coronary stents is exceptionally rigorous due to their classification as high-risk medical devices. Manufacturers must navigate a complex landscape of regulations, ensuring compliance with numerous safety and efficacy standards. The process of obtaining necessary approvals can be both time-consuming and costly, creating additional hurdles for companies aiming to bring new technologies to market. This regulatory burden can slow down innovation and limit the availability of advanced stenting solutions, affecting overall market growth.
Economic Pressures and Ethical Considerations
Economic factors pose another layer of challenge within the coronary stents market. The high costs associated with advanced stent technologies, particularly drug-eluting and bioresorbable stents, can restrict access to treatment, especially in low- and middle-income countries where healthcare budgets are limited. As a result, many patients may not receive timely interventions, leading to adverse health outcomes. Moreover, the intense competition among manufacturers can lead to price erosion, squeezing profit margins and making it difficult for companies to sustain investments in research and development. This competitive landscape is further complicated by the presence of generic stents and alternative treatment options, which intensify price pressures and challenge market dynamics. Additionally, there is a growing need for comprehensive long-term data on the efficacy and safety of newer devices, particularly bioresorbable stents, as existing evidence remains limited. Addressing ethical considerations surrounding patient selection and responsible use of coronary stents is crucial for optimizing outcomes and preventing unnecessary procedures. Manufacturers must navigate these ethical dilemmas while ensuring that patients receive informed counseling regarding device selection and treatment options, thereby fostering trust and confidence in the technology. Together, these challenges highlight the complexities of the coronary stents market and underscore the importance of continuous innovation, ethical practice, and regulatory compliance to enhance patient care and market stability.
Market Segmentation Analysis:
By Product:
The coronary stents market can be segmented by product into Drug-Eluting Stents (DES), Bare Metal Stents (BMS), and Bioresorbable Vascular Stents (BVS). DES continues to dominate the market due to their proven efficacy in preventing restenosis through the controlled release of medication. These stents are increasingly preferred for their long-term benefits, leading to a growing adoption rate among healthcare professionals. BMS, while effective, are experiencing a decline in preference as patients and providers lean toward more advanced technologies that offer superior outcomes. However, BMS remain essential for specific patient demographics, particularly those with limited access to DES due to cost or regulatory issues. BVS is an emerging segment that presents significant potential for future growth. These stents dissolve over time, thereby reducing the need for a permanent foreign body in the artery. As research continues to improve their design and performance, BVS is expected to gain traction in the market, appealing to both patients and healthcare providers looking for innovative solutions in coronary interventions.
By Raw Material:
Another critical segmentation of the coronary stents market is based on raw materials, including Cobalt-Chromium, Stainless Steel, Platinum-Chromium, Nickel-Titanium, and Polymer. Cobalt-Chromium stents are favored for their superior strength and biocompatibility, making them suitable for complex procedures. Stainless Steel remains a popular choice due to its cost-effectiveness and reliability, although its usage is gradually declining in favor of more advanced materials. Platinum-Chromium offers enhanced visibility under fluoroscopy and improved mechanical properties, positioning it as a competitive option in the market. Nickel-Titanium, known for its unique shape-memory properties, is ideal for specific applications where flexibility and resilience are essential. Meanwhile, Polymer-based stents are gaining attention due to advancements in drug delivery systems and coating technologies. Each material offers distinct advantages that cater to various patient needs and procedural requirements, influencing the overall dynamics of the coronary stents market. The continuous evolution of raw material technology is expected to drive further innovation and improvements in stent performance and patient outcomes.
Segments:
Based on Product:
- Drug Eluting Stent (DES)
- Bare Metal Stent (BMS)
- Bioresorbable Vascular Stent (BVS)
Based on Raw Material:
- Cobalt-Chromium
- Stainless Steel
- Platinum – Chromium
- Nickel – Titanium
- Polymer
Based on End User:
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Catheterization Laboratories
Based on the Geography:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis
North America
North America holds a significant share of the global coronary stents market, accounting for approximately 35%. This dominance is attributed to advanced healthcare infrastructure, high adoption rates of innovative medical technologies, and a strong emphasis on research and development. The United States, in particular, leads the region, driven by increasing cardiovascular disease prevalence and a growing aging population. The availability of cutting-edge coronary stents, such as Drug-Eluting Stents (DES) and Bioresorbable Vascular Stents (BVS), has further enhanced treatment options for patients. Additionally, robust reimbursement policies and government initiatives aimed at improving healthcare access are propelling market growth in this region. As awareness regarding heart diseases and preventive care continues to rise, the demand for coronary stents is expected to maintain its upward trajectory, solidifying North America’s position as a leader in the market.
Asia-Pacific
In contrast, the Asia-Pacific region is rapidly emerging as a key player in the coronary stents market, projected to capture approximately 30%. This growth is driven by several factors, including a rising middle class with increased healthcare spending, improved healthcare infrastructure, and heightened awareness of cardiovascular diseases. Countries like China and India are witnessing a surge in demand for coronary stent procedures, fueled by a high incidence of heart diseases linked to lifestyle changes and aging populations. Moreover, the region’s focus on adopting minimally invasive procedures, such as Percutaneous Coronary Intervention (PCI), has significantly boosted the adoption of coronary stents. As investments in healthcare continue to expand and technology evolves, the Asia-Pacific market is poised for substantial growth, providing opportunities for both local and global manufacturers in the coronary stent sector.
Key Player Analysis
- Abbott
- BD
- Boston Scientific Corporation
- Biotronik SE & Co. KG
- Medtronic
- MicroPort Scientific Corporation
- Cook
- Braun Melsungen AG
- Terumo Corporation
Competitive Analysis
The competitive landscape of the coronary stents market is characterized by significant innovation and a focus on enhancing patient outcomes. Leading players such as Abbott, Medtronic, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, BD, MicroPort Scientific Corporation, B. Braun Melsungen AG, and Cook are at the forefront of this market. These companies are investing heavily in research and development to introduce advanced stent technologies, including drug-eluting and bioresorbable stents, to reduce the risk of restenosis and improve long-term patient outcomes. Furthermore, strategic partnerships and collaborations are common among these firms to expand their product offerings and enhance their market presence globally. Price competition is also a significant factor, as companies strive to balance cost-effectiveness with quality to meet the demands of healthcare providers and patients alike. As a result, the market remains dynamic, with ongoing advancements and shifting competitive dynamics.
Recent Developments
- In April 2023, Terumo Europe N.V., the European arm of a leading Japanese medical device company, announced the start of its new clinical study for a coronary stent system, which received a CE mark approval in November 2022. The study explores the use of Ultimaster Nagomi™ sirolimus eluting coronary stent system in complex PCI patients.
- In January 2023, The F.D.A. approved the BioFreedom Drug Coated Coronary Stent System, which is designed to treat coronary artery disease-related constriction of the blood vessels in patients at high risk for bleeding due to certain conditions. The stent is coated with Biolimus A9, which is slowly released to prevent re-narrowing. In a primary clinical study, patients who received the BioFreedom stent were able to discontinue one of their blood-thinning medications after a month without an increase in the risk of death or heart attack. This approval adds to the competitive landscape of the coronary stent market, giving physicians and patients an additional option.
- In January 2022, MicroPort established its US headquarters in Irvine, California with facilities that include a manufacturing base and innovation center. As of 2022, its principal business is valued at over US$6.5 Billion. Micro Port is a multinational medical technology developer and manufacturer that is primarily headquartered in Shanghai, China. It mainly designs and produces medical devices for a range of fields including cardiology, interventional radiology, orthopedics, electrophysiology, and surgical management. Micro Port is considered one of the Medtech Big 100 and has been consistently known as the leading spender in research and development by percentage of revenue.
- In October 2022, Cordis, a leading interventional cardiovascular technology manufacturer, acquired Swiss medical technology company MedAlliance. Cordis will invest $235 million upfront till 2029, with up to $1.135 billion for regulatory and commercial milestones. MedAlliance’s SELUTION (Sustained Limus Release) drug-eluting balloon (D.E.B.) product line will expand Cordis’ product line, sales, marketing, and distribution.
Market Concentration & Characteristics
The market concentration of coronary stents is characterized by a mix of established global players and emerging companies, leading to a competitive yet fragmented landscape. Major manufacturers, including Abbott, Medtronic, and Boston Scientific, dominate the market, collectively holding a substantial share due to their extensive product portfolios and continuous innovation. The presence of these key players enhances market stability while fostering advancements in technology, such as drug-eluting and bioresorbable stents, which improve patient outcomes and reduce complications. Additionally, the market features a range of smaller companies that contribute to niche segments, focusing on specialized products or innovative solutions. This diversity drives competition and encourages technological development, resulting in better options for healthcare providers and patients. Furthermore, regulatory challenges and stringent quality standards necessitate significant investment in research and development, thereby influencing market dynamics and promoting high-quality products that meet evolving healthcare needs.Top of Form
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage
The research report offers an in-depth analysis based on Product, Raw Material, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
- The coronary stents market is expected to grow significantly due to the increasing prevalence of cardiovascular diseases.
- Technological advancements will lead to the development of next-generation stents, including bioresorbable options and improved drug-eluting stents.
- The demand for minimally invasive procedures will continue to drive the adoption of coronary stents.
- Rising healthcare expenditure and improved access to medical facilities will enhance market growth, particularly in emerging economies.
- The integration of digital technologies and telemedicine will facilitate better patient monitoring and outcomes post-stent placement.
- Ongoing clinical trials will yield more data on the long-term efficacy and safety of newer stent technologies.
- Increasing competition among manufacturers will lead to innovative product offerings and more competitive pricing.
- Regulatory bodies will likely continue to enforce stringent approval processes, ensuring product safety and effectiveness.
- The focus on personalized medicine will influence the selection and design of coronary stents based on individual patient needs.
- Greater awareness and education about cardiovascular health will drive early diagnosis and treatment, further boosting demand for stent procedures.
